Ren et al. reported that MDS patients with mutations in the RAS pathway (including NRAS, KRAS, CBL, PTPN11, and NF1) demonstrate a higher IPSS-R classification, a shorter OS, and a higher rate of AML transformation [211]. The gene discussed is KRAS; the disease is acute myeloid leukemia.